$Kala制药(KALA)$  “We are pleased to announce the addition of EYSUVIS to Cigna’s preferred formulary, reflecting a significant expansion of our commercial coverage and important progress toward our goal of securing broad patient access,” said Todd Bazemore, Chief Operating Officer of Kala Pharmaceuticals. “We look forward to continuing to engage with other commercial and Medicare Part D health plans as we execute on our strategy to optimize coverage, with the goal of delivering EYSUVIS as the preferred prescription therapy for the millions of people in the United States who suffer from dry eye disease flares.”

划重点:  

a significant expansion of our commercial coverage; 

the millions of people in the United States